Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA )

41.92 -0.39 (-0.92%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 158,565
Open 42.43
Bid (Size) 32.23 (3)
Ask (Size) 62.79 (1)
Prev. Close 42.31
Today's Range 41.33 - 42.44
52wk Range 14.20 - 51.61
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire

Performance

YTD
+168.55%
+168.55%
1 Month
-11.32%
-11.32%
3 Month
-6.68%
-6.68%
6 Month
+24.32%
+24.32%
1 Year
+162.33%
+162.33%

More News

Read More
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
Via Investor's Business Daily
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Vera Therapeutics to Participate at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.